Get the Stockscreener App
3.30
6.45%
+0.20
Repare Therapeutics Inc stock is currently priced at $3.30, with a 24-hour trading volume of 203.90K.
It has seen a +6.45% increased in the last 24 hours and a -29.79% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.13 pivot point. If it approaches the $3.35 resistance level, significant changes may occur.
Previous Close:
$3.10
Open:
$3.09
24h Volume:
203.90K
Market Cap:
$139.20M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-22.00
EPS:
-0.15
Net Cash Flow:
$-129.10M
1W Performance:
+0.00%
1M Performance:
-29.79%
6M Performance:
-5.44%
1Y Performance:
-64.17%
1D Range:
$3.09
$3.50
52W Range:
$2.98
$13.85
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
857 412 7018
Address
7210 Frederick-Banting, Suite 100, Montreal, QC
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks Investment Research
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Zacks Investment Research
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Zacks Investment Research
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Zacks Investment Research
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Benzinga
Repare Therapeutics Inc Stock (RPTX) Financials Data
Repare Therapeutics Inc (RPTX) Revenue 2024
RPTX reported a revenue (TTM) of $51.13 million for the quarter ending December 31, 2023, a -61.21% decline year-over-year.
Repare Therapeutics Inc (RPTX) Net Income 2024
RPTX net income (TTM) was -$93.80 million for the quarter ending December 31, 2023, a -222.91% decrease year-over-year.
Repare Therapeutics Inc (RPTX) Cash Flow 2024
RPTX recorded a free cash flow (TTM) of -$129.10 million for the quarter ending December 31, 2023, a -46,006% decrease year-over-year.
Repare Therapeutics Inc (RPTX) Earnings per Share 2024
RPTX earnings per share (TTM) was -$2.23 for the quarter ending December 31, 2023, a -185.90% decline year-over-year.
About Repare Therapeutics Inc
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It also develops CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montréal, Canada.
3.18%
Cap:
|
Volume (24h):